Welcome to LookChem.com Sign In|Join Free

CAS

  • or

15001-08-8

Post Buying Request

15001-08-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

15001-08-8 Usage

General Description

ETHYL 5-AMINO-1-(3-CHLOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE is a chemical compound with the molecular formula C12H12ClN3O2. It is a pyrazole derivative with a chlorine-substituted phenyl group and an ethyl ester group. This chemical is commonly used as an intermediate or building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It may also have potential applications in medicinal chemistry and drug discovery due to its structural properties. However, it is important to handle this compound with caution, as it may have specific handling and storage requirements due to its potentially hazardous or reactive nature.

Check Digit Verification of cas no

The CAS Registry Mumber 15001-08-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,0,0 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 15001-08:
(7*1)+(6*5)+(5*0)+(4*0)+(3*1)+(2*0)+(1*8)=48
48 % 10 = 8
So 15001-08-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H12ClN3O2/c1-2-18-12(17)10-7-15-16(11(10)14)9-5-3-4-8(13)6-9/h3-7H,2,14H2,1H3

15001-08-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 5-amino-1-(3-chlorophenyl)pyrazole-4-carboxylate

1.2 Other means of identification

Product number -
Other names ethyl 5-amino-1-(3-chlorophenyl)-1H-pyrazole-4-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:15001-08-8 SDS

15001-08-8Downstream Products

15001-08-8Relevant articles and documents

Synthesis of pyrazole-carboxamides and pyrazole-carboxylic acids derivatives: Simple methods to access powerful building blocks

Ferreira, Byanca Silva,Silva, Rafaela Corrêa,Souto, Bernardo Araújo,Dos Santos, Maurício Silva

, p. 335 - 343 (2021/09/07)

Hybrid systems containing pyrazole moiety show a wide spectrum of biological activities. To access novel hybrids with pyrazole ring, in this work we synthesized twenty pyrazole-carboxylic acids and twenty pyrazole-carboxamides, using simple synthetic methods, to be used as building blocks in the development of new structures.

Targeting Pim Kinases and DAPK3 to Control Hypertension

Carlson, David A.,Singer, Miriam R.,Sutherland, Cindy,Redondo, Clara,Alexander, Leila T.,Hughes, Philip F.,Knapp, Stefan,Gurley, Susan B.,Sparks, Matthew A.,MacDonald, Justin A.,Haystead, Timothy A.J.

, p. 1195 - 32,1207 (2018/07/06)

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS

-

Paragraph 00321, (2013/03/26)

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 15001-08-8